SCHEMBL6445453

SCHEMBL6445453

CC(CNc1ccccc1)Nc1nc(N)nc(-c2ccco2)c1C#N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 13/20 0.55
ADORA1 P30542 11/20 0.55
ADORA2B P29275 5/20 0.55
ALDH1A1 P00352 7/20 0.42
HPGD P15428 7/20 0.42
KDM4E B2RXH2 6/20 0.42
GAA P10253 4/20 0.42
TDP1 Q9NUW8 2/20 0.42
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 1/20 0.41
CASP1 P29466 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.40
LMNA P02545 3/20 0.40
POLB P06746 1/20 0.40
SMARCA2 P51531 1/20 0.40
MAPT P10636 1/20 0.38
STAT6 P42226 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036673 0.83 ADORA2A (0.61) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL29623091 0.82 ADORA2A (0.60) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL23204316 0.82 ADORA2A (0.60) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6446015 0.79 ADORA2A (0.61) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL5040171 0.78 ADORA2A (0.62) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6440820 0.77 ALDH1A1 (0.54) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6441851 0.77 ADORA2A (0.64) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6441991 0.76 ADORA2A (0.57) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL7147912 0.76 ADORA2A (0.52) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL7150146 0.76 ADORA2A (0.52) ADORA2AADORA1ADORA2BALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.